Why Rheumatoid Arthritis Hits Indian Women Three Times More Often Than Men, And What Drives It

Rheumatoid arthritis affects roughly 0.5 to 1 percent of India's adult population, but that burden is not distributed evenly. Women account for nearly 75 percent of all RA cases globally, and data from the Indian Rheumatology Association places the female-to-male ratio in India at close to 3:1. A 2019 study published in the Journal of Family Medicine and Primary Care found that Indian women with RA were also significantly more likely than men to present late, often years after symptoms began, because joint pain in women is routinely attributed to calcium deficiency or general fatigue rather than an autoimmune process. The delay matters. RA does its worst structural damage in the first two years of active inflammation. Every month of missed diagnosis is cartilage that does not come back.
The immune system in women is, by design, more aggressive than in men. This is partly why women mount stronger responses to infections and vaccines, but it is also why autoimmune diseases cluster in women at two to three times the male rate across nearly every condition in the category, from lupus to thyroid disease to RA. Estrogen is the primary driver. It amplifies the activity of B cells, which produce the antibodies that, in rheumatoid arthritis, mistakenly attack the synovial lining of joints. During reproductive years, when estrogen levels are high and fluctuating, this immune amplification runs continuously. The clinical evidence is consistent: RA symptoms frequently worsen in the week before menstruation when estrogen drops sharply, improve during pregnancy when a different hormonal profile suppresses inflammation, and then spike again in the postpartum period. For Indian women who go through multiple pregnancies with limited postnatal recovery time and nutritional support, this postpartum flare window is a recurring risk point that rarely gets medical attention.
India has a paradox that researchers have documented repeatedly: a sun-drenched country with widespread vitamin D deficiency. A 2014 study in the Indian Journal of Endocrinology and Metabolism found that over 70 percent of Indian women had insufficient or deficient vitamin D levels. This matters for RA because vitamin D functions as an immune modulator. Low levels are associated with higher rates of autoimmune activation and more severe inflammatory responses once a condition like RA is established. Indian women who spend most of their time indoors, whether in urban apartments or working inside the home, absorb less sunlight than men who work outdoors. Dietary sources of vitamin D are limited in predominantly vegetarian diets. Calcium absorption, which depends on vitamin D, also suffers, and low calcium is one of the conditions that gets blamed when a woman reports joint pain, sending her away with a supplement instead of a rheumatology referral.
The structural problem compounds the biological one. In most Indian households, a woman reporting persistent joint pain is more likely to be told to rest, apply oil, or take a painkiller than to be sent for an anti-CCP antibody test, which is the specific blood marker for rheumatoid arthritis. The anti-CCP test is inexpensive and widely available, but it requires a doctor who considers RA as a possibility in the first place. General practitioners in India, according to a 2020 analysis in the Indian Journal of Rheumatology, often lack the training to distinguish early RA from osteoarthritis or fibromyalgia, and women's pain complaints are more frequently dismissed or undertreated than men's across multiple specialties. By the time many Indian women reach a rheumatologist, they have already developed joint erosion visible on X-ray. At that stage, treatment can slow progression, but the damage already done is permanent.

There is also a genetic layer specific to the South Asian population. The HLA-DRB1 gene variant, which significantly raises RA risk, appears at higher frequencies in South Asian populations than in European ones. Women carrying this variant who also have low vitamin D, high estrogen fluctuation, and limited access to early diagnosis face a convergence of risks that no single factor explains on its own. Research from the Sanjay Gandhi Postgraduate Institute of Medical Sciences in Lucknow has identified that Indian RA patients tend to have more aggressive joint inflammation at presentation than Western cohorts, suggesting either a more severe disease phenotype in this population, or the consequence of longer untreated inflammation before diagnosis, or both.
The three-times figure is not a statistical accident. It is the sum of an immune system tuned for vigilance, hormones that keep that vigilance elevated for decades, a nutrition gap that removes one of the body's key brakes on autoimmune activity, and a medical system that has not yet learned to take a woman's joint pain as seriously as it takes a man's. Each of those factors is addressable individually. None of them has been addressed systematically.